The FDA announced on November 22, 2022, that Fresenius Kabi USA, LLC voluntarily recalled Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000. The product is subpotent because testing results fell below the defined limit for the epinephrine portion.
How to tell if you have it
- Brand: Fresenius Kabi
- Product: Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL
- Packaging: 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-463-57)
- Batch #: 6128399, 6128400, 6128401
- Expiration: 04/2024
- Units affected: 40,025 vials
The hazard
The recall is due to the product being a subpotent drug. Testing results were below the defined limit for the epinephrine portion of Sensorcaine.
Context
GovInfoNow's records show Fresenius Kabi USA, LLC has 65 other recalls on record since September 27, 2012. Other recent recalls of similar products include Fresenius Kabi Tyenne Injection Recall (August 10, 2026), Fresen: Morphine Syringes May Have Wrong Labeling (August 4, 2026), and Fresenius Kabi Xylocaine 1% Injection Recall (July 16, 2026). Other recent recalls of similar products include Fresenius Kabi Ketamine HCl Injection Recall (February 5, 2026), Fresenius Kabi Thiamine HCl Injection Recall (February 5, 2026), and Fresenius Kabi acyclovir injection recall (February 5, 2026).